Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin

Wataru Ichikawa, Akio Ooyama, Etsuko Toda, Yoshikazu Sugimoto, Toshinori Oka, Takehiro Takahashi, Michio Shimizu, Yasutsuna Sasaki, Renzo Hirayama

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Ferredoxin reductase (FDXR) is a putative contributor to p53-mediated apoptosis from 5-fluorouracil (5-FU) through the generation of oxidative stress in the mitochondria. However, the influence of FDXR gene expression levels on the outcome of 5-FU chemotherapy has been relatively little studied. The aim of this study is to investigate the association between FDXR gene expressions and the clinical outcome when treated by 5-FU chemotherapy, as well as the correlation of FDXR gene expressions and p53 mutation. Methods: Pre-chemotherapeutic fresh frozen samples of 33 patients with metastatic colorectal cancer, who received bolus 5-FU and leucovorin (LV) as first line chemotherapy, were studied. FDXR gene expression and p53 mutation were evaluated by real-time RT-PCR and direct sequencing, respectively. Results: FDXR gene expression was significantly higher in responding tumors compared with non-responding ones (P=0.0379). Patients with FDXR values above the cutoff value of 13.52 had a statistically longer survival than those with FDXR gene expressions below the cutoff value (P=0.0148). The 9 tumors with wild-type p53 had statistically higher FDXR gene expressions than the 14 tumors with mutant-type p53 which had sequence alterations within the "hot spot" codons, the L2-L3 loops, or frameshift (P=0.0463). Conclusions: FDXR gene expression did not affect clinical outcome in patients with wild-type p53 tumors, whereas, among patients with p53 mutant-type tumors, patients with tumors with low FDXR gene expression had a worse outcome than those with a high FDXR gene expression (P=0.0200). FDXR gene expression, which is regulated at least in part by p53, is associated with both response and survival when metastatic colorectal cancer is treated with 5-FU plus LV. In addition, analysis of p53 mutation combined with FDXR gene expression might be useful in estimating the outcome in 5-FU-treated patients.

Original languageEnglish
Pages (from-to)794-801
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume58
Issue number6
DOIs
Publication statusPublished - 2006 Dec
Externally publishedYes

Fingerprint

Ferredoxins
Leucovorin
Gene expression
Fluorouracil
Colorectal Neoplasms
Oxidoreductases
Gene Expression
Tumors
Chemotherapy
Neoplasms
Drug Therapy
Mutation
Mitochondria
Oxidative stress
Survival
Codon

Keywords

  • 5-FU
  • Colorectal cancer
  • Ferredoxin reductase
  • p53 mutation

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin. / Ichikawa, Wataru; Ooyama, Akio; Toda, Etsuko; Sugimoto, Yoshikazu; Oka, Toshinori; Takahashi, Takehiro; Shimizu, Michio; Sasaki, Yasutsuna; Hirayama, Renzo.

In: Cancer Chemotherapy and Pharmacology, Vol. 58, No. 6, 12.2006, p. 794-801.

Research output: Contribution to journalArticle

Ichikawa, Wataru ; Ooyama, Akio ; Toda, Etsuko ; Sugimoto, Yoshikazu ; Oka, Toshinori ; Takahashi, Takehiro ; Shimizu, Michio ; Sasaki, Yasutsuna ; Hirayama, Renzo. / Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin. In: Cancer Chemotherapy and Pharmacology. 2006 ; Vol. 58, No. 6. pp. 794-801.
@article{4673a1c69f3a49a6a3b01bd1974ec6aa,
title = "Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin",
abstract = "Purpose: Ferredoxin reductase (FDXR) is a putative contributor to p53-mediated apoptosis from 5-fluorouracil (5-FU) through the generation of oxidative stress in the mitochondria. However, the influence of FDXR gene expression levels on the outcome of 5-FU chemotherapy has been relatively little studied. The aim of this study is to investigate the association between FDXR gene expressions and the clinical outcome when treated by 5-FU chemotherapy, as well as the correlation of FDXR gene expressions and p53 mutation. Methods: Pre-chemotherapeutic fresh frozen samples of 33 patients with metastatic colorectal cancer, who received bolus 5-FU and leucovorin (LV) as first line chemotherapy, were studied. FDXR gene expression and p53 mutation were evaluated by real-time RT-PCR and direct sequencing, respectively. Results: FDXR gene expression was significantly higher in responding tumors compared with non-responding ones (P=0.0379). Patients with FDXR values above the cutoff value of 13.52 had a statistically longer survival than those with FDXR gene expressions below the cutoff value (P=0.0148). The 9 tumors with wild-type p53 had statistically higher FDXR gene expressions than the 14 tumors with mutant-type p53 which had sequence alterations within the {"}hot spot{"} codons, the L2-L3 loops, or frameshift (P=0.0463). Conclusions: FDXR gene expression did not affect clinical outcome in patients with wild-type p53 tumors, whereas, among patients with p53 mutant-type tumors, patients with tumors with low FDXR gene expression had a worse outcome than those with a high FDXR gene expression (P=0.0200). FDXR gene expression, which is regulated at least in part by p53, is associated with both response and survival when metastatic colorectal cancer is treated with 5-FU plus LV. In addition, analysis of p53 mutation combined with FDXR gene expression might be useful in estimating the outcome in 5-FU-treated patients.",
keywords = "5-FU, Colorectal cancer, Ferredoxin reductase, p53 mutation",
author = "Wataru Ichikawa and Akio Ooyama and Etsuko Toda and Yoshikazu Sugimoto and Toshinori Oka and Takehiro Takahashi and Michio Shimizu and Yasutsuna Sasaki and Renzo Hirayama",
year = "2006",
month = "12",
doi = "10.1007/s00280-006-0217-6",
language = "English",
volume = "58",
pages = "794--801",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin

AU - Ichikawa, Wataru

AU - Ooyama, Akio

AU - Toda, Etsuko

AU - Sugimoto, Yoshikazu

AU - Oka, Toshinori

AU - Takahashi, Takehiro

AU - Shimizu, Michio

AU - Sasaki, Yasutsuna

AU - Hirayama, Renzo

PY - 2006/12

Y1 - 2006/12

N2 - Purpose: Ferredoxin reductase (FDXR) is a putative contributor to p53-mediated apoptosis from 5-fluorouracil (5-FU) through the generation of oxidative stress in the mitochondria. However, the influence of FDXR gene expression levels on the outcome of 5-FU chemotherapy has been relatively little studied. The aim of this study is to investigate the association between FDXR gene expressions and the clinical outcome when treated by 5-FU chemotherapy, as well as the correlation of FDXR gene expressions and p53 mutation. Methods: Pre-chemotherapeutic fresh frozen samples of 33 patients with metastatic colorectal cancer, who received bolus 5-FU and leucovorin (LV) as first line chemotherapy, were studied. FDXR gene expression and p53 mutation were evaluated by real-time RT-PCR and direct sequencing, respectively. Results: FDXR gene expression was significantly higher in responding tumors compared with non-responding ones (P=0.0379). Patients with FDXR values above the cutoff value of 13.52 had a statistically longer survival than those with FDXR gene expressions below the cutoff value (P=0.0148). The 9 tumors with wild-type p53 had statistically higher FDXR gene expressions than the 14 tumors with mutant-type p53 which had sequence alterations within the "hot spot" codons, the L2-L3 loops, or frameshift (P=0.0463). Conclusions: FDXR gene expression did not affect clinical outcome in patients with wild-type p53 tumors, whereas, among patients with p53 mutant-type tumors, patients with tumors with low FDXR gene expression had a worse outcome than those with a high FDXR gene expression (P=0.0200). FDXR gene expression, which is regulated at least in part by p53, is associated with both response and survival when metastatic colorectal cancer is treated with 5-FU plus LV. In addition, analysis of p53 mutation combined with FDXR gene expression might be useful in estimating the outcome in 5-FU-treated patients.

AB - Purpose: Ferredoxin reductase (FDXR) is a putative contributor to p53-mediated apoptosis from 5-fluorouracil (5-FU) through the generation of oxidative stress in the mitochondria. However, the influence of FDXR gene expression levels on the outcome of 5-FU chemotherapy has been relatively little studied. The aim of this study is to investigate the association between FDXR gene expressions and the clinical outcome when treated by 5-FU chemotherapy, as well as the correlation of FDXR gene expressions and p53 mutation. Methods: Pre-chemotherapeutic fresh frozen samples of 33 patients with metastatic colorectal cancer, who received bolus 5-FU and leucovorin (LV) as first line chemotherapy, were studied. FDXR gene expression and p53 mutation were evaluated by real-time RT-PCR and direct sequencing, respectively. Results: FDXR gene expression was significantly higher in responding tumors compared with non-responding ones (P=0.0379). Patients with FDXR values above the cutoff value of 13.52 had a statistically longer survival than those with FDXR gene expressions below the cutoff value (P=0.0148). The 9 tumors with wild-type p53 had statistically higher FDXR gene expressions than the 14 tumors with mutant-type p53 which had sequence alterations within the "hot spot" codons, the L2-L3 loops, or frameshift (P=0.0463). Conclusions: FDXR gene expression did not affect clinical outcome in patients with wild-type p53 tumors, whereas, among patients with p53 mutant-type tumors, patients with tumors with low FDXR gene expression had a worse outcome than those with a high FDXR gene expression (P=0.0200). FDXR gene expression, which is regulated at least in part by p53, is associated with both response and survival when metastatic colorectal cancer is treated with 5-FU plus LV. In addition, analysis of p53 mutation combined with FDXR gene expression might be useful in estimating the outcome in 5-FU-treated patients.

KW - 5-FU

KW - Colorectal cancer

KW - Ferredoxin reductase

KW - p53 mutation

UR - http://www.scopus.com/inward/record.url?scp=33748475139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748475139&partnerID=8YFLogxK

U2 - 10.1007/s00280-006-0217-6

DO - 10.1007/s00280-006-0217-6

M3 - Article

VL - 58

SP - 794

EP - 801

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -